CMPS - צמיחת הכנסות משנה לשנה ב-12 החודשים האחרונים COMPASS Pathways plc

The high scalability potential of COMPASS Pathways plc (CMPS) is driven by low costs following the certification of its psilocybin-based therapy. The YoY commercial revenue growth for the LTM reflects the current trend, where the metric value stands at 0.00. Patent protection for the COMP360 molecule establishes a foundation for market dominance, while the development strategy relies on academic partnerships without external acquisitions.

This indicator integrates quarterly reports and market quotes into a continuous stream, measuring business expansion dynamics via a rolling annual revenue growth rate. By analyzing the current year-over-year (TTM) revenue growth, investors assess the ability of COMPASS Pathways plc (CMPS) to monetize its patent protection for synthetic psilocybin under strict FDA oversight, where any deceleration in growth rates signals regulatory risks.